Ventyx Biosciences, Inc. (VTYX): Price and Financial Metrics
GET POWR RATINGS... FREE!
VTYX Stock Price Chart Interactive Chart >
VTYX Price/Volume Stats
| Current price | $16.80 | 52-week high | $26.00 |
| Prev. close | $14.85 | 52-week low | $9.50 |
| Day low | $15.33 | Volume | 223,600 |
| Day high | $16.91 | Avg. volume | 135,838 |
| 50-day MA | $13.60 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 854.28M |
Ventyx Biosciences, Inc. (VTYX) Company Bio
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Latest VTYX News From Around the Web
Below are the latest news stories about Ventyx Biosciences Inc that investors may wish to consider to help them evaluate VTYX as an investment opportunity.
We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative ColitisVTX002 is an oral, peripherally-restricted, selective sphingosine 1 phosphate receptor 1 (S1P1) receptor modulator internally discovered and developed by the team at VentyxENCINITAS, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today that the first patient has |
Ventyx Biosciences (VTYX) Initiated with a Buy at LifeSci CapitalVentyx Biosciences (VTYX – Research Report) received a Buy rating and a $40.00 price target from LifeSci Capital analyst Sam Slutsky on November 15. The company's shares closed last Monday at $21.76. According to TipRanks.com, Slutsky is a 3-star analyst with an average return of 6.8% and a 41.9% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Sierra Oncology, and BELLUS Health. Currently, the analyst consensus on Ventyx Biosciences is a Strong Buy with an average price target of $42.50, which is a 95.8% upside from current levels. |
Ventyx Biosciences to Participate in Two Upcoming Investor ConferencesENCINITAS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview at the following upcoming investor conferences: Event: 4th Annual Evercore ISI HealthCONx ConferenceLocation: Virt |
Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business UpdateWholly-owned pipeline with three clinical-stage programs targeting significant inflammatory and immunology disease markets Dosing initiated in a multiple-ascending dose (MAD) Phase 1 trial for VTX958, an oral, selective tyrosine kinase type 2 (TYK2) inhibitor, and a Phase 1 trial for VTX2735, an oral Nod-like receptor protein 3 (NLRP3) inhibitor Completed upsized initial public offering (IPO) of common stock, raising approximately $174.3 million in gross proceeds, including full exercise of unde |
VTYX Price Returns
| 1-mo | N/A |
| 3-mo | 43.10% |
| 6-mo | -21.42% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -15.41% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...